Adelaide, Australia—Ellex Medical Lasers Ltd. has acquired the canaloplasty business of U.S.-based iScience Interventional Inc., which comprises the iTrack 250 catheter and suture device for the treatment of mild-moderate glaucoma.
“This acquisition is very exciting,” said Tom Spurling, chief executive officer of Ellex. “The new canaloplasty business will allow us to provide our existing customers with the complementary product offering for the treatment of glaucoma.”
Current customers of the iTrack 250 device will join Ellex as well, he said.
“Combined with our SLT laser product portfolio, which targets the early stage of glaucoma, (the device) will enable Ellex to cement its position as the global leader in early to moderate glaucoma treatment intervention,” Spurling said.
The business will now trade as Ellex iScience Inc. Production of the device will continue to be undertaken out of the existing FDA-approved facility at Menio Park in the Bay Area of San Francisco, while expansion of the canaloplasty clinical training team will begin immediately in order to better support existing and new customers.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.